- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06343428
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients (TAPIOCA)
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients: an observAtional, Prospective Analysis of the Correlation Between Functional Imaging and Clinical Outcome (TAPIOCA)
The 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated neuroendocrine neoplasms (NENs) that called neuroendocrine tumors (NETs) G3 in pancreatic NENs classification and, then, in 2019, for all gastro-entero-pancreatic (GEP) tract NENs.
The new classification made it possible to separate NETs G3 from high-grade, poorly-differentiated, NENs that are called neuroendocrine carcinomas (NECs).
However, in clinical practice, we observed that several clinical, pathological and radiological differences are arising among NET G3 patients, suggesting that a multiparametric definition of NET G3 is needed.
Study Overview
Status
Conditions
Detailed Description
High-grade neuroendocrine neoplasms (NENs) represent the poorest prognosis category within NENs. During the years, the prognostic differences among the subgroups led to identify at least two subcategories of high-grade NENs, according the morphologic features of the two subtypes.
Indeed, the 2017 World Health Organization (WHO) introduced a new category of high-grade, well-differentiated NENs that called neuroendocrine tumors (NETs) G3 for pancreatic NENs and, then, in 2019, for all gastro-entero-pancreatic (GEP) tract NENs, allowing to separate NET G3 from the other high-grade, poorly-differentiated, NENs, so called neuroendocrine carcinomas (NECs).
However, since the new-category has been introduced, NET G3 category seemed to be more heterogeneous than presumed. Indeed, clinical, pathological and radiological features seemed to identify different prognostic subcategories of NET G3. We recently performed a retrospective analysis on a small pool of 48 NET G3 patients, correlating the clinical outcomes with these different features. The results of our study seemed to suggest prognostic and predictive factors that deserve to be prospectively explored to better understand this pathology and that might to be part of NET G3 multiparametric classification system. Based on the results of our retrospective analysis, we underlined the importance of a systematic and well-designed collection of high-quality data in order to improve our knowledge on this topic.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Cristina Mazzon
- Email: cristina.mazzon@ieo.it
Study Contact Backup
- Name: Francesca Spada, MD
- Phone Number: +390257489258
- Email: divisione.gastrointestinale@ieo.it
Study Locations
-
-
-
Milan, Italy, 20141
- Recruiting
- European Institute of Oncology
-
Principal Investigator:
- Francesca Spada, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histological diagnosis of well-differentiated neuroendocrine tumor G3 performed or reviewed by a NEN-dedicated pathologist. In case of "late-NET G3" (see Patients and Methods), a NEN-dedicated pathologist will perform a pathologic review of the previous NET G1/2, too, unless a NEN-dedicated pathologist has already done and except for diagnoses performed in a NEN-referral Center.
- Age > 18 years
- Signed written informed consent
- Available tumor tissue (formalin-fixed paraffin-embedded, FFPE) (preferably within 6 months). If the tumor contained in FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut. Preferably, 25 slides should be provided (minimum of 15 slides). If tumor tissue is not available, patients should be willing to undergone to a new biopsy.
- late-NET G3 patients that will come to our Institute at the moment of NET G3 diagnosis will be enrolled only if they performed 68 Gallium-DOTATOC positron emission tomography (PET)/CT and 18 fluorodeoxyglucose (FDG)-PET/CT for the previous NET G1/2. The previous functional imaging performed during the NET G1/2 history shall be available for the review by our specialist in nuclear medicine.
Exclusion Criteria:
- Diagnosis of well-differentiated NET G1/2 or poorly-differentiated NEC
- Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) in which a NET G3 as neuroendocrine component
- Cytological diagnosis of NET G3 or not availability of tumor tissue for pathological analysis
- Concurrent neoplastic disease (e.g. advanced breast or prostatic cancer in hormonal treatment, hematologic diseases)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
NET G3 patients
Histological diagnosis of well-differentiated neuroendocrine tumor G3 performed or reviewed by a NEN-dedicated pathologist.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunohistochemical characteristics analysis
Time Frame: 3 years
|
Analysis of the morphology Analysis of proliferation index Ki-67 Analysis of Ki-67 expression (as hotspot or a diffuse expression on the sample) Analysis of Synaptophysin, and chromogranin expression
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Review of the functional imaging
Time Frame: 3 years
|
Analysis of homogeneity or inhomogeneity of radiotracer distribution Analysis of the concordance/discordance between functional imaging.
For "late-NET G3", the specialist in nuclear medicine will review both functional imaging (before and after NET G3 diagnosis)
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Francesca Spada, MD, Istituto Europeo di Oncologia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IEO 1519
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Neoplasm
-
Roswell Park Cancer InstituteNot yet recruitingMalignant Solid Neoplasm | Lung Neuroendocrine Neoplasm | Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingCarcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditionsUnited States
-
M.D. Anderson Cancer CenterTerSera Therapeutics LLCRecruitingLocally Advanced Neuroendocrine Neoplasm | Metastatic Neuroendocrine NeoplasmUnited States
-
Amr Mohamed MDNovatek PharmaceuticalsRecruitingNeuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine NeoplasmUnited States
-
National Cancer Center, ChinaRecruitingRectal Neuroendocrine NeoplasmChina
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Neuroendocrine Neoplasm | Metastatic Neuroendocrine Carcinoma | Metastatic Large Cell Neuroendocrine Carcinoma | Metastatic Small Cell Neuroendocrine CarcinomaUnited States, Canada
-
University of WashingtonEli Lilly and CompanyRecruitingLocally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Metastatic Digestive System Neuroendocrine Neoplasm | Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Digestive System Neuroendocrine Tumor | Foregut Neuroendocrine Tumor | Hindgut Neuroendocrine... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); NovartisCompletedIntermediate Grade Lung Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Functional Pancreatic Neuroendocrine Tumor | Advanced Digestive System Neuroendocrine Neoplasm | Duodenal Neuroendocrine Tumor G1 | Gastric Neuroendocrine Tumor | Nonfunctional Pancreatic Neuroendocrine... and other conditionsUnited States
-
Bavarian Cancer RegistryBavarian Association of Statutory Health Insurance Accredited PhysiciansNot yet recruitingNeuroendocrine Neoplasm of Lung | Neuroendocrine Neoplasm of Gastrointestinal Tract (Disorder)